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Abstract
Breast cancer-associated bone metastasis induces bone loss, followed by an increased risk of bone 
fracture. To develop a strategy for preventing tumor growth and protecting bone, an understanding 
of the mechanical properties of bone under tumor burden is indispensable. Using a mouse model 
of mammary tumor, we conducted finite element analysis (FEA) of two bone samples from the 
distal femur. One sample was from a placebo-treated mouse, and the other was from a mouse 
treated with the investigational drug candidate, PD407824, an inhibitor of checkpoint kinases. 
Mechanical testing and microCT images revealed that bone strength is improved by administration 
of PD407824. In response to loading to the knee, FEA predicted that the peaks of von Mises 
stress, an indicator of fracture yielding, as well as the third principal compressive stress, were 
higher in the placebo-treated femur than the drug-treated femur. Higher peak stresses in trabecular 
segments were observed in the lateral condyle, a critical region for integrity of the knee joint. 
Collectively, this FE study supports the notion that mechanical weakening of the femur was 
observed in the tumor-invaded trabecular bone, and chemical agents such as PD407824 may 
potentially assist in preventing bone loss and bone fracture.
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Introduction
Breast cancer is a serious health problem for women in the U.S. and the rest of the world (1). 
Tumors at the primary site may be treated surgically or chemically, but they frequently 
metastasize to other organs, such as the lungs and brain (2). Bone is one of the most frequent 
sites of metastasis from breast cancer (3). Currently, drugs such as bisphosphonates are 
administered to reduce bone pain and fracture that are associated with osteolytic reactions in 
metastasized bone, but there are few treatment options that stop tumor migration and cure 
bone metastasis (4, 5).
To develop new drugs for suppressing both tumor growth and bone loss, mouse models of 
mammary tumor and bone metastasis have been employed for testing candidate agents (6). 
One such drug candidate is everolimus, which is a mammalian target of rapamycin (mTOR) 
inhibitor (7). Everolimus is approved as an anti-tumor agent for advanced estrogen receptor-
positive breast cancer. Another drug candidate is a modulator of dopamine signaling, 
A77636, which induces apoptosis in tumor cells and inhibits maturation of bone-resorbing 
osteoclasts (8). We recently examined the effects of inhibitors of checkpoint kinases (Chks), 
which regulate DNA damage responses and cell cycling, on bone metastasis (9).
In this study, we focused on the effect of PD407824 (10), a selective inhibitor of checkpoint 
kinase 1 (Chk1), on the distal femur of the mouse knee joint. Activation of Chk1 results in 
cell cycle arrest, and its mutations are reported to be linked to breast and other cancers (11). 
Administration of Chk inhibitors for inhibiting tumor growth has been considered (12, 13), 
and we recently reported the effects of these inhibitors on suppression of bone resorption 
(14). In this report, we showed that Chk1 inhibitors blocked the proliferation, survival, and 
migration of tumor cells in vitro and suppressed the development of bone-resorbing 
osteoclasts by downregulating nuclear factor of activated T cells (NFATc1), a master 
transcription factor for osteoclast development.
The study herein was conducted to characterize the effects of the drug candidate PD407824 
on mechanical properties of the mouse distal femur. We first conducted animal experiments 
and analyzed drug effects using approaches such as X-ray imaging, mechanical testing, 
microCT imaging, and histology. We then performed FE (finite element) analysis of the 
distal femur in response to a lateral force applied to the medial side of the condyle, to 
quantify bone stiffness and strength.
Materials and Methods
Animal model
The experimental procedure was approved by the Indiana University Animal Care and Use 
Committee and was in compliance with the Guiding Principles in the Care and Use of 
Animals endorsed by the American Physiological Society. BALB/c female mice were fed 
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with mouse chow and water ad libitum. They received an injection of 4T1.2 mammary 
tumor cells (1.0 × 105 cells in 50 μl PBS) (15) to the right iliac artery. PD407824 was 
administered daily via i.p. injection at 2 mg/kg body weight. The animals were sacrificed on 
day 17. A whole-body X-ray was taken at 25 kV for 10 sec using a Faxitron radiographic 
system (Faxitron X-ray Corporation) (8), and the femora were harvested for 
characterization.
Mechanical testing
The whole femur was loaded to failure by four-point bending using a voltage-regulated 
mechanical loading device (Electro Force 3100, Bose, Inc.), with a loading span of 2.3 mm 
and a support span of 7 mm (16). Load was applied to the longitudinal center of the 
diaphysis. After applying a 0.5 N preload, the bone was loaded monotonically at 0.03 mm/s 
to failure. During bending, displacement and load were recorded to calculate stiffness.
μCT imaging
Micro-computed tomography was performed using a Skyscan 1172 microCT scanner 
(Bruker-MicroCT, Kontich Belgium) (17). The harvested bone samples were wrapped in 
parafilm to maintain hydration and placed in a plastic tube and oriented vertically. Scans 
were performed at pixel size 8.99 μm. Using manufacturer-provided software, the images 
were reconstructed (nRecon v1.6.9.18).
Histology
Right lower limb specimens were fixed in 10% neutral buffered formalin (Thermo Fisher 
Scientific) for 48 h and demineralized in 10% EDTA (pH 7.4) at 4°C for three weeks. The 
samples were dehydrated in graded alcohol and cleared with xylenes (Fisher). Samples were 
embedded in paraffin, sectioned at 5-μm thicknesses along the sagittal plane, and stained 
with hematoxylin and eosin for examining metastasized tumor. The nuclei of tumor cells 
tend to be dyskaryotic and enlarged, and they stained differently with blue-based 
hematoxylin (8).
Finite element (FE) analysis
FE analysis was conducted using ANSYS workbench 14.5 (ANSYS, Pennsylvania) for two 
distal femur samples (G1–10 and G6–7). Using microCT images, the medial half of the 
distal femur was segmented with MIMICS 16 (Materialise, Belgium) and meshed with 3-
matic (Materialise, Belgium). We focused on the medial half of distal femur (lateral 
condyle), which was meshed into ~750,000 tetrahedral elements. The sagittal plane (plane of 
symmetry) was fixed, and two loading cases were considered: a lateral load of 10 N was 
applied to the tip of the femur, or the condyle (knee loading). The deformations and stresses 
resulting from the applied loads were computed.
The average the Hounsfield units (HU) of the placebo and the treated samples were −895.5 
and −896.3, respectively. Since differences in HU are negligible between the two samples, 
the same setting of MIMICS was used to process the CT images of the two femur samples. 
The HU value is directly related to bone mineral density and Yong’s modulus. In this 
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analysis, we employed Young’s modulus of 8.9 GPa and Poisson’s ratio of 0.35. The main 
focus of this study was thus the effect of structural differences in deformation and stress.
Results
Induction of bone metastasis in the mouse model
Metastatic mammary tumor cells were inoculated to mice via the right iliac artery, and 
invasion of tumor cells in the right hindlimb was induced in two animal groups (10 mice 
each). According to X-ray imaging, all animals showed induction of bone metastasis in the 
distal femur. One group was a placebo group that received an equal volume of vehicle, while 
the other was a PD407824-treated group that received daily injections of an investigational 
drug agent, PD407824 (Fig. 1A). In FE analysis in this study, we focused on one 
representative mouse from each treatment group. X-ray images of these two mice on day 17 
after inoculation of tumor cells display inflamed muscle around the right femur (Fig. 
1B&C). While the PD407824-treated mouse appeared to have denser bone in the distal 
femur than placebo based on the X-ray’s image density, further analysis was needed to 
evaluate bone quality.
Effects of PD407824 treatment on whole bone strength, trabecular density, and tumor 
burden
Mechanical testing of the femur using four-point bending showed that compared to the 
placebo group, the PD407824-treated group showed a significant increase in stiffness (p = 
0.02). The number of samples was 10 for both groups. Hereafter, we focused on two 
representative samples. MicroCT imaging and the reconstruction of 3-dimensional structure 
of these two samples revealed that compared to placebo, the PD407824-treated sample had 
denser trabecular bone in the distal femur (Fig. 2B). Furthermore, histological analysis using 
hematoxylin and eosin staining showed that the placebo-treated femur had a region of 
invaded tumor cells proximal to the growth plate (Fig. 2C). No tumor cells were visible in 
PD407824-treated sample.
Effects of PD407824 treatment on FE-derived stiffness and von Mises stress
The stiffness of the condyle was determined by displacement in the direction of force 
application at the loading site, divided by the distance, d, from the loading site to the sagittal 
plane (Fig. 3). Of note, we used average displacement in local region surrounding loading 
site and avoided numerical instability due to the stress concentration at the loading site. The 
predicted stiffness for the two loading cases (BC1 and BC2) are summarized (Tables 1 & 2), 
while the deformation in the direction of lateral loading is illustrated (Figs. 4 & 5).
Next, we determined the distribution of von Mises stress in two loading cases (Figs. 6 & 7). 
In both samples, high stresses were predicted in the intercondylar fossa (between medial and 
lateral condyles). This area was selected for the stress comparison (Table 3). Of note, the 
high stress at the loading site and the sagittal plane was not analyzed further due to potential 
uncertainties resulting from stress concentrations and constraints. The failure resistance is 
characterized by von Mises stress. Since von Mises stress of the PD407824-treated femur 
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was lower than that of the placebo, the result is in concert with a higher failure resistance of 
the treated sample.
Effects of PD407824 treatment on third principal stress
Consistent with the predicted von Mises stress, the third principal stress (compressive stress 
as negative values) presented similar features (Figs. 8 & 9). In response to lateral loading, 
the placebo sample showed a larger area of high compression (50 MPa or more in the blue 
zone) at the loading site as well as a wider distribution of high compression in the cross-
section. The maximum stress in the intercondylar fossa was compared in two samples (Table 
3).
Discussion
This study demonstrates that metastatic invasion of mammary tumor cells to the distal femur 
reduces local mechanical properties, whereas daily administration of the investigational drug 
PD407824 prevented metastasis and the consequent reduction in mechanical properties. We 
employed a mouse model of mammary tumor and bone metastasis in which mammary tumor 
cells, 4T1.2, were inoculated to the right iliac artery. This tumor cell line is a metastatic 
triple negative cell line, which is immuno-compatible to BALB/c mice. In response to 
external loading at 10 N force, which was applied to the lateral condyle, von Mises stress as 
well as the maximum compressive stress showed peaks at the intercondylar fossa (between 
medial and lateral condyles). Those peak stresses extended across a wider area in the 
placebo femur than the PD407824-treated femur, indicating higher stresses in the placebo 
femur.
The treatment with PD407824 improved both stiffness and strength of the distal femur with 
higher capacity to withstand loads. MicroCT image analysis revealed that the average HU of 
the two samples were virtually identical, indicating that a potential change in material 
properties was negligible. This study was therefore focused on geometric or volumetric 
changes and their effects on stiffness and stress distributions. The FE analysis revealed that 
the treatment resulted in a stiffer structure than the untreated placebo. We observed a 
significant increase in stiffness in the treated sample that produced a >50% decrease in 
stress. The increase in failure resistance was also demonstrated by reduction in von Mises 
and maximum compressive stresses.
The predicted mechanical properties by FE analysis are consistent with the experimental 
results from mechanical testing, microCT imaging, and histological analysis. In FE 
modeling, the two bone samples had a bone volume of 7.39 mm3 (placebo) and 9.00 mm3 
(PD407824-treated). Stiffness of the whole femur in four-point bending was 62.37 N/mm 
(placebo) and 104.12 N/mm (PD407824-treated). Histological analysis together with 
microCT imaging revealed that the volume of trabecular bone was lower in the placebo 
sample than the PD407824-treated sample. Of note, the lower volume in placebo was 
consistent with a region of tumor invasion proximal to the growth plate in the distal femur.
The checkpoint kinase inhibitor PD407824 is an investigational drug candidate that 
selectively inhibits checkpoint kinase 1 (Chk1) and is being considered for treatment of 
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various types of cancers. While the effects of Chk1 inhibitors on tumor cells have been 
reported (18), their role in development of bone-forming osteoblasts and bone-resorbing 
osteoclasts need to be examined. In our previous study, we conducted in vitro and in vivo 
analysis for evaluating the role of PD407824 on MC3T3 osteoblast-like cells as well as 
RAW264.7 pre-osteoclast cells and found that PD407824 is an effective inhibitor of bone 
degradation in addition to its anti-tumor effects (14). The current study further supports its 
potential benefit in preserving bone mechanical properties from degradation by metastatic 
tumor.
While the present study focused on the distal femur, bone metastasis may occur in other 
bones, including the spine (19). Bisphosphonates such as zoledronic acid and pamidronate 
are the standard of care for treating bone metastasis. In future studies, bisphosphonate-
treated samples as well as the normal control sample will be compared to the placebo and 
PD407824-treated samples, and the spine will also be analyzed.
There are limitations in this study. While our FE analysis was focused on two representative 
bone samples, there are variations in stiffness among animals as shown in Fig. 2A. These 
variations can be affected not only by efficacy of PD407824 but also size and geometry of 
individual samples. Of note, the overall weight of animals was not significantly different 
among the two groups. Although we evaluated the effects of PD407824 in comparison to the 
placebo sample, the normal control without inoculation of tumor cells presented higher 
stiffness than the placebo and PD407824-treated samples (data not shown). In summary, this 
study shows that an integrated analysis using imaging, histological, and FE approaches is 
useful to comprehensively characterize the mechanical properties of the tumor-invaded bone 
samples for evaluation of investigational treatment. We found that trabecular bone becomes 
a target of osteolytic responses that appear to elevate the peak von Mises stress. Future 
structural characterization of bone metastasis therapies may allow more targeted protection 
of specific bone types.
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Figure 1. 
X-ray images of the placebo and PD407824-treated mice. (A) Chemical structure of 
PD407824, a selective inhibitor of checkpoint kinase 1. The red circle indicates the distal 
femur. (B) X-ray image of the placebo mouse (G1–10). (C) X-ray image of PD407824-
treated mouse (G6–7). The red circle indicates the distal femur.
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Figure 2. 
Mechanical testing, micro CT images, and histology. (A) Stiffness of the femoral shaft using 
four-point bending. Two samples, employed in this study (G1–10 from the placebo group 
and G6–7 from the PD407824-treated group), are marked in red. (B) Three-dimensionally 
reconstructed micro CT images of the distal femur. (C) Hematoxylin and eosin staining of 
the distal femur. The area, covered by the dotted line in placebo, is invaded with tumor cells.
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Figure 3. 
Location of the two loading sites (BC1 and BC2) on the two distal femurs in this study. (A) 
Placebo sample. (B) PD407824-treated sample. (C) Loading sites on the condyle from the 
lateral view.
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Figure 4. 
Deformation in the force direction by lateral loading at the condyle edge (BC1). (A) Placebo 
sample. (B) PD407824-treated sample.
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Figure 5. 
Deformation in the force direction by lateral loading at the condyle center (BC2). (A) 
Placebo sample. (B) PD407824-treated sample.
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Figure 6. 
von-Mises stress in response to lateral loading at the condyle edge (BC1). (A) Surface and 
cross-sectional stresses of the placebo sample. (B) Surface and cross-sectional stresses of 
PD407824-treated sample.
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Figure 7. 
von-Mises stress in response to lateral loading at the condyle center (BC2). (A) Surface and 
cross-sectional stresses of the placebo sample. (B) Surface and cross-sectional stresses of 
PD407824-treated sample.
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Figure 8. 
Third principal stress in response to lateral loading at the condyle edge (BC1). (A) Surface 
and cross-sectional stresses of the placebo sample. (B) Surface and cross-sectional stresses 
of PD407824-treated sample.
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Figure 9. 
Third principal stress in response to lateral loading at the condyle center (BC2). (A) Surface 
and cross-sectional stresses of the placebo sample. (B) Surface and cross-sectional stresses 
of PD407824-treated sample.
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Table 1
Stiffness in response to the loading on the tip.
Sample d Average displacement Stiffness
Placebo 1.89 mm 0.040 mm 0.0212
PD407824-treated 1.84 mm 0.027 mm 0.0145
Note: Compared to the placebo femur, the strain of the treated femur decreased 31%.
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Table 2
Stiffness in response to the loading on the condyle.
Sample d Average displacement Stiffness
Placebo 1.82 mm 0.048 mm 0.0251
PD407824-treated 1.76 mm 0.040 mm 0.0218
Note: Compared to the placebo femur, the strain of the treated femur decreased 53%.
Int J Orthop (Hong Kong). Author manuscript; available in PMC 2019 February 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Jiang et al. Page 19
Table 3
Stresses at the intercondylar fossa.
Stress (boundary condition) Placebo (MPa) Treated (MPa) %Decrease
von-Mises stress (BC1) 250 105 58
von-Mises stress (BC2) 71 25 64
3rd principle stress (BC1) −274 −130 52
3rd principle stress (BC2) −81 −30 62
Int J Orthop (Hong Kong). Author manuscript; available in PMC 2019 February 28.
